Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Metronidazole Induced Cutaneous Adverse Drug Reaction- A Systematic Review of Descriptive Studies

Author(s): Shifa Taj, Mohammed Zuber*, Vidhyashree Ballagere Hanumanthaiah, Rajesh Venkataraman, Sathish Kumar Puttegowda, Syed Afrid and Sai Kiran

Volume 19, Issue 3, 2024

Published on: 03 August, 2023

Page: [269 - 284] Pages: 16

DOI: 10.2174/2772432819666230601155545

Price: $65

Abstract

Background: A substantial number of research studies on metronidazole-related cutaneous symptoms have recently been published. Our objective was to identify and evaluate descriptive studies that described metronidazole-related skin manifestations, therapeutic interventions, and consequences.

Methods: A comprehensive literature search was carried out in the PubMed, Scopus, and grey literature databases from inception to April 2022 without any constraints, as well as a snowball search in Google and a search in Google Scholar. Descriptive articles describing metronidazole-related cutaneous manifestations were considered for the review. Two distinct reviewers carried out the research selection, data extraction, and quality assessment; any discrepancies were resolved by consensus with the third reviewer.

Results: About 24 out of 4648 descriptive studies, including 26 patients (20 Female patients and 6 male patients), were included in this review. The included studies comprised a range of ages from 16 to 78 years old. Metronidazole was indicated for the treatment of bacterial vaginosis, trichomoniasis, sepsis, anti-infection therapy, perforated appendicitis, rosacea, vaginal discharge, dysentery, acne rosacea, trichomonal vaginitis, lichen planus, liver abscess, facial rosacea, intestinal amoebiasis, and gingivitis. Fixed drug eruption was the most common skin manifestation which was reported in 7 cases included in this review. Cutaneous manifestations were ameliorated by cessation of the offending drug and by apportioning antihistamines, topical steroids, parenteral corticosteroids, emollients, and topical moisturizers.

Conclusion: Clinicians and healthcare professionals should be cognizant of the potential cutaneous adverse drug reactions (CADRs) induced by metronidazole to mitigate fatal circumstances. The management of the CADRs appears to respond effectively with immediate drug discontinuation and supportive therapy.

Keywords: Metronidazole, adverse effect, cutaneous reaction, skin manifestation, case report, systematic review.

« Previous Next »
Graphical Abstract

[1]
Leitsch D. A review on metronidazole: An old warhorse in antimicrobial chemotherapy. Parasitology 2019; 146(9): 1167-78.
[http://dx.doi.org/10.1017/S0031182017002025] [PMID: 29166971]
[2]
Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010; 50(S1): S16-23.
[http://dx.doi.org/10.1086/647939] [PMID: 20067388]
[3]
Weir CB, Le JK. Metronidazole. StatPearls. Treasure Island, FL: StatPearls Publishing 2022.
[4]
Vardanyan RS. Hruby, Victor. Drugs for Treating Protozoan Infections 2006.
[http://dx.doi.org/10.1016/B978-044452166-8/50037-6]
[5]
Hernández CA, Romero-Quezada LC, Ruvalcaba LJC, López CL. Therapeutic uses of metronidazole and its side effects: An update. Eur Rev Med Pharmacol Sci 2019; 23(1): 397-401.
[http://dx.doi.org/10.26355/eurrev_201901_16788] [PMID: 30657582]
[6]
Jackson EA, Cardoni AA, Stranz MH, Bradley WE. New drug evaluations: Metronidazole (Flagyl IV®, Searle). Drug Intell Clin Pharm 1981; 15(11): 838-46.
[http://dx.doi.org/10.1177/106002808101501101] [PMID: 7028437]
[7]
Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23(5): 328-64.
[http://dx.doi.org/10.2165/00003088-199223050-00002] [PMID: 1478003]
[8]
Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36(5): 353-73.
[http://dx.doi.org/10.2165/00003088-199936050-00004] [PMID: 10384859]
[9]
Nagel JL, Aronoff DM. Metronidazole. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th. 350-358.e4.
[10]
Yang F, Jiang M, Zhang W, et al. HLA-A*24:02 is associated with metronidazole-induced cutaneous adverse drug reactions in Han Chinese individuals: A pilot case-control study with both HLA gene and T cell receptor repertoire analysis. Basic Clin Pharmacol Toxicol 2020; 126(2): 133-43.
[http://dx.doi.org/10.1111/bcpt.13315] [PMID: 31483922]
[11]
Rashid M, Rajan AK, Chhabra M, Kashyap A. Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies. Seizure 2020; 75: 101-9.
[http://dx.doi.org/10.1016/j.seizure.2020.01.002] [PMID: 31931437]
[12]
Zuber M, et al. Harikrishna, Vidhyashree, Methotrexate related cutaneous adverse drug reactions: A systematic literature review. J Basic Clin Physiol Pharmacol 2022; 33(5): 549-65.
[http://dx.doi.org/10.1515/jbcpp-2021-0165] [PMID: 34706401]
[13]
Vidhyashree BH, Zuber M, Taj S, Venkataraman R, Kumar BP, Jabeen N. Rasburicase induced methemoglobinemia: A systematic review of descriptive studies. J Oncol Pharm Pract 2022; 1078155221075239.
[http://dx.doi.org/10.1177/10781552221075239] [PMID: 35119341]
[14]
Howick J, Chalmers I, Glasziou P. The oxford 2011 levels of evidence. Oxford, UK: Oxford Centre for Evidence-Based Medicine 2011.
[15]
Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 2018; 23(2): 60-3.
[http://dx.doi.org/10.1136/bmjebm-2017-110853] [PMID: 29420178]
[16]
Aktürk A, Bayramgürler D, Salman S. Yıldız KD, Demirsoy E. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by oral metronidazole. Cutan Ocul Toxicol 2014; 33(4): 337-8.
[http://dx.doi.org/10.3109/15569527.2013.823981] [PMID: 24938451]
[17]
Bhaduri S, Riley VC. Metronidazole hypersensitivity in a patient with bacterial vaginosis. Int J STD AIDS 1997; 8(1): 57-8.
[http://dx.doi.org/10.1258/0956462971918625] [PMID: 9043984]
[18]
Connolly R, Russell S. Acute oromucosal and palmar desquamation: a severe cutaneous adverse reaction to amphotericin and metronidazole. BMJ Case Rep 2014; 2014: bcr2014205501.
[http://dx.doi.org/10.1136/bcr-2014-205501] [PMID: 24925542]
[19]
Gastaminza G, Anda M, Audicana MT, Fernandez E, Muñoz D. Fixed-drug eruption due to metronidazole with positive topical provocation. Contact Dermat 2001; 44(1): 54-5.
[http://dx.doi.org/10.1034/j.1600-0536.2001.440107-3.x] [PMID: 11156011]
[20]
Hermida MD, Consalvo L, Lapadula MM, Della GP, Cabrera HN. Bullous fixed drug eruption induced by intravaginal metronidazole ovules, with positive topical provocation test findings. Arch Dermatol 2011; 147(2): 250-1.
[http://dx.doi.org/10.1001/archdermatol.2010.419] [PMID: 21339462]
[21]
Huang J, Zhu X, Jiang C, Liu Z. A case report of rash induced by cefoperazone sodium and sulbactam sodium plus metronidazole sodium chloride combined with morphine hydrochloride. Ann Palliat Med 2020; 9(6): 4377-83.
[http://dx.doi.org/10.21037/apm-20-2192] [PMID: 33302688]
[22]
Iio K, Ariyama Y, Tomita H, Sakakibara H, Hataya H. Secondary haemophagocytic lymphohistiocytosis associated with metronidazole. Postgrad Med J 2019; 95(1125): 390.
[http://dx.doi.org/10.1136/postgradmedj-2019-136512] [PMID: 31123179]
[23]
Fernández-Jorge B, Buján J, Fernández-Torres R, Rodríguez-Lojo R, Fonseca E. Concomitant allergic contact dermatitis from diphenhydramine and metronidazole. Contact Dermat 2008; 59(2): 115-6.
[http://dx.doi.org/10.1111/j.1600-0536.2008.01332.x] [PMID: 18759879]
[24]
Knowles S, Choudhury T, Shear NH. Metronidazole hypersensitivity. Ann Pharmacother 1994; 28(3): 325-6.
[http://dx.doi.org/10.1177/106002809402800305] [PMID: 8193418]
[25]
Kostaki M, Polydorou D, Adamou E, Chasapi V, Antoniou C, Stratigos A. Acute localized exanthematous pustulosis due to metronidazole. J Eur Acad Dermatol Venereol 2019; 33(3): e109-11.
[http://dx.doi.org/10.1111/jdv.15274] [PMID: 30288796]
[26]
Kumagai J, Nakamura A, Ogawa S, Washio K. Intravaginal metronidazole ovule-related allergic contact dermatitis. Contact Dermat 2021; 85(1): 85-6.
[http://dx.doi.org/10.1111/cod.13782] [PMID: 33423284]
[27]
Kumar N, Sundriyal D, Walia M, Trisal D. Metronidazole-induced fixed drug eruption. BMJ Case Rep 2013; 2013: bcr2013200470.
[http://dx.doi.org/10.1136/bcr-2013-200470] [PMID: 24217927]
[28]
Madsen JT, Thormann J, Kerre S, Andersen KE, Goossens A. Allergic contact dermatitis to topical metronidazole? 3 cases. Contact Dermat 2007; 56(6): 364-6.
[http://dx.doi.org/10.1111/j.1600-0536.2006.01064.x] [PMID: 17577385]
[29]
Maize JC, Tomecki KJ. Pityriasis rosea-like drug eruption secondary to metronidazole. Arch Dermatol 1977; 113(10): 1457-8.
[http://dx.doi.org/10.1001/archderm.1977.01640100135034] [PMID: 911179]
[30]
Mazumdar G, Shome K. Stevens-Johnson syndrome following use of metronidazole in a dental patient. Indian J Pharmacol 2014; 46(1): 121-2.
[http://dx.doi.org/10.4103/0253-7613.125193] [PMID: 24550598]
[31]
Moitra S, Sen S, Banerjee I, Sikder A, Das P. Metronidazole-induced bullous pemphigoid: A case report. J Clin Diagn Res 2015; 9(12): FD01-3.
[http://dx.doi.org/10.7860/JCDR/2015/14669.6972] [PMID: 26816913]
[32]
Mussani F, Skotnicki S. Recall dermatitis to metronidazole. J Cutan Med Surg 2015; 19(3): 326-7.
[http://dx.doi.org/10.2310/7750.2014.14135] [PMID: 25775652]
[33]
Naik RPC, Singh G. Fixed drug eruption due to metronidazole. Dermatology 1977; 155(1): 59-60.
[http://dx.doi.org/10.1159/000250957] [PMID: 144074]
[34]
Piskin G, Mekkes JR. Stevens-Johnson syndrome from metronidazole. Contact Dermat 2006; 55(3): 192-3.
[http://dx.doi.org/10.1111/j.1600-0536.2006.00904.x] [PMID: 16918620]
[35]
Sehgal VN, Khandpur S, Sardana K, Bajaj P. Bullous fixed drug eruption (BFDE) following per-oral metronidazole. J Eur Acad Dermatol Venereol 2003; 17(5): 607-9.
[http://dx.doi.org/10.1046/j.1468-3083.2003.00722.x] [PMID: 12941113]
[36]
Short KA, Salisbury JR, Fuller LC. Fixed drug eruption following metronidazole therapy and the use of topical provocation testing in diagnosis. Clin Exp Dermatol 2002; 27(6): 464-6.
[http://dx.doi.org/10.1046/j.1365-2230.2002.01067.x] [PMID: 12372086]
[37]
Vila JB, Bernier MA, Gutierrez JV, et al. Fixed drug eruption caused by metronidazole. Contact Dermat 2002; 46(2): 122.
[http://dx.doi.org/10.1034/j.1600-0536.2002.460219.x] [PMID: 11918615]
[38]
Wolf R, Orion E, Matz H. Co-existing sensitivity to metronidazole and isothiazolinone. Clin Exp Dermatol 2003; 28(5): 506-7.
[http://dx.doi.org/10.1046/j.1365-2230.2003.01364.x] [PMID: 12950340]
[39]
Zhang H, Xie Z. Symmetrical drug-related intertriginous and flexural exanthema induced by metronidazole suppository. Contact Dermat 2021; 84(6): 486-8.
[http://dx.doi.org/10.1111/cod.13780] [PMID: 33421140]

Rights & Permissions Print Cite
Article Metrics
28
2
© 2024 Bentham Science Publishers | Privacy Policy